• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【分子编号】53975

【品名】2-[6-(dimethylamino)-3-pyridinyl]-3-[(Z)hydrazono]butanenitrile

【CA登记号】n/a

【 分 子 式 】C11H15N5

【 分 子 量 】217.2738

【元素组成】C 60.81% H 6.96% N 32.23%

与该中间体有关的原料药合成路线共 1 条

合成路线1

该中间体在本合成路线中的序号:(IV)

The condensation of 2-[6-(dimethylamino)pyridin-3-yl]acetonitrile (I) with ethyl acetate (II) by means of NaH in THF gives 2-[6-(dimethylamino)pyridin-3-yl]-3-oxobutyronitrile (III), which is treated with hydrazine in refluxing ethanol/water to yield the corresponding hydrazone (IV). The cyclization of (IV) with ethyl acetoacetate (V) in refluxing dioxane affords 3-[6-(dimethylamino)pyridin-3-yl]-2,5-dimethylpyrazolo[2,3-a]pyrimidin-7-ol (VI), which is treated with refluxing POCl3 to provide the expected 7-chloro derivative (VII). Finally, this compound is treated with dipropylamine (VIII) in refluxing acetonitrile to furnish the target dipropylamino derivative.

1 Chen, C.; Webb, T.R.; McCarthy, J.R.; Moran, T.J.; Wilcoxen, K.M. (Janssen Pharmaceutica NV; Neurocrine Biosciences Inc.); Pyrazolopyrimidines as CRF receptor antagonists. EP 0880523; JP 2000503661; WO 9729109 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 53973 2-[6-(dimethylamino)-3-pyridinyl]acetonitrile n/a C9H11N3 详情 详情
(II) 17491 ethyl acetate 141-78-6 C4H8O2 详情 详情
(III) 53974 2-[6-(dimethylamino)-3-pyridinyl]-3-oxobutanenitrile n/a C11H13N3O 详情 详情
(IV) 53975 2-[6-(dimethylamino)-3-pyridinyl]-3-[(Z)hydrazono]butanenitrile n/a C11H15N5 详情 详情
(V) 11819 ethyl acetoacetate; ethyl 3-oxobutanoate;Acetoacetic ester;Ethyl beta-ketobutyrate;ethyl 3-oxobutyrate 141-97-9 C6H10O3 详情 详情
(VI) 53976 3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol n/a C15H17N5O 详情 详情
(VII) 53977 N-[5-(7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-2-pyridinyl]-N,N-dimethylamine; 5-(7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-dimethyl-2-pyridinamine n/a C15H16ClN5 详情 详情
(VIII) 21856 N,N-dipropylamine; N-propyl-1-propanamine 142-84-7 C6H15N 详情 详情
Extended Information